There are many well-established correlations between warfarin dosing and therapeutic endpoints. One realm we’re still working to conquer includes the influence of genetics on the application of warfarin and other medicines. Ann Wittkowsky, PharmD, director of anticoagulation services at the University of Washington Medical Center in Seattle, joins host Dr. Charles Turck to examine the potential impact of genetics in pharmacotherapeutics.
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Genetics in Anticoagulant Pharmacotherapy
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Comments
Overview
Recommended
Details
Presenters
Comments
Overview
There are many well-established correlations between warfarin dosing and therapeutic endpoints. One realm we’re still working to conquer includes the influence of genetics on the application of warfarin and other medicines. Ann Wittkowsky, PharmD, director of anticoagulation services at the University of Washington Medical Center in Seattle, joins host Dr. Charles Turck to examine the potential impact of genetics in pharmacotherapeutics.